Trials / Conditions / Relapsed or Refractory Acute Myeloid Leukemia

Relapsed or Refractory Acute Myeloid Leukemia

15 registered clinical trials studyying Relapsed or Refractory Acute Myeloid Leukemia — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R NCT06879847	The First Affiliated Hospital of Soochow University	N/A
Recruiting	Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT06812104	Kyowa Kirin Co., Ltd.	Phase 1
Terminated	A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms NCT05787496	NextCure, Inc.	Phase 1
Recruiting	Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia NCT05726110	Shanxi Bethune Hospital	Phase 3
Recruiting	Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia NCT05522192	Hui Zeng	Phase 1 / Phase 2
Terminated	A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leu NCT05038800	Merck Sharp & Dohme LLC	Phase 1
Completed	Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia NCT04666649	University of Maryland, Baltimore	Phase 1
Terminated	Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia NCT04478695	Amgen	Phase 1
Unknown	Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of NCT04842370	Seoul National University Hospital	Phase 1
Terminated	Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia NCT03765541	University Hospital, Toulouse	Phase 3
Completed	A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation NCT04176393	CStone Pharmaceuticals	Phase 1
Terminated	Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, NCT03755154	Institut de Recherches Internationales Servier	Phase 1
Terminated	AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants Wit NCT02675452	Amgen	Phase 1
Terminated	CD123 Redirected Autologous T Cells for AML NCT02623582	University of Pennsylvania	EARLY_Phase 1
Withdrawn	Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia NCT02215629	Verastem, Inc.	Phase 1